A5044284945- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Brain Metastases and Treatment
- Cutaneous lymphoproliferative disorders research
- Nonmelanoma Skin Cancer Studies
- Immunotherapy and Immune Responses
- PI3K/AKT/mTOR signaling in cancer
- Inflammatory Myopathies and Dermatomyositis
- Ocular Oncology and Treatments
- Cancer and Skin Lesions
- Colorectal Cancer Treatments and Studies
- Nail Diseases and Treatments
- COVID-19 and healthcare impacts
- T-cell and Retrovirus Studies
- Optical Coherence Tomography Applications
- HER2/EGFR in Cancer Research
- Genital Health and Disease
- Cell Adhesion Molecules Research
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Protein Tyrosine Phosphatases
- Vascular Tumors and Angiosarcomas
- Dermatological diseases and infestations
Hôpital Ambroise-Paré
2014-2023
Université Paris-Saclay
2016-2023
Assistance Publique – Hôpitaux de Paris
2007-2023
Université de Versailles Saint-Quentin-en-Yvelines
2009-2022
Agroécologie
2012-2018
Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie
2018
Institut Curie
2011-2015
Inserm
2009-2011
Centre Hospitalier Universitaire Amiens-Picardie
2011
Centre National de la Recherche Scientifique
2009-2011
Immune checkpoint inhibitors (ICI) significantly improve overall survival (OS) in patients with advanced melanoma, but immune-related colitis may occur and warrant anti-tumor necrosis factor α (TNFα) treatment severe forms. A nationwide, multicenter retrospective survey was conducted to assess both, the real-life incidence of grade 3/4 ICI-induced treated anti-TNFα, consequence this therapeutic strategy on disease outcome. All melanoma anti-TNFα agents for ICI-related participating centers...
Information on the role of radiotherapy in anti-PD-1 monoclonal antibody-treated melanoma patients is limited. We report a prospective cohort advanced treated simultaneously with and therapy between 01/01/15 30/06/16. Tumor evaluations (RECIST 1.1) were performed every 3 months radiated non-radiated lesions. Twenty-five (64% AJCC stage IV M1c, 64% second-line treatment or more, 60% elevated LDH serum levels) included. Radiotherapy was early (median: 24 days) after first dose 15 rapidly...
Abstract Loss of the tumour suppressor PTEN is frequent in human melanoma, results MAPK activation, suppresses senescence and mediates metastatic behaviour. How loss these effects unknown. Here we show that epithelial melanocytic cell lines induces nuclear localization transcriptional activation β-catenin independent PI3K–AKT–GSK3β axis. The absence leads to caveolin-1 (CAV1)-dependent modulation vitro , cooperates with NRAS Q61K initiate melanomagenesis vivo efficient metastasis formation...
<h3>Importance</h3> This case series highlights the risk of uveitis in patients treated with vemurafenib for unresectable or metastatic cutaneous melanoma. <h3>Objective</h3> To assess occurrence and severity as an adverse effect therapy. <h3>Design, Setting, Patients</h3> In this observational small series, data were collected successively from May 1, 2012, through February 31, 2013, clinical signs ocular inflammation at Department Ophthalmology, Cochin-Hôtel-Dieu Hospital. <h3>Main...
The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyse the current strategies irM and evaluate outcomes immune checkpoint inhibitors (ICIs) rechallenge.We conducted a nationwide retrospective study between April 2018 March 2020 including without myocardial involvement. Depending on presence cutaneous signs or unusual histopathological features, patients were classified into two groups: typical atypical irM. Therapeutic...
To evaluate the ability of high-resolution ultrasonography (hrUS) to detect sentinel-node (SN) melanoma metastases preoperatively before biopsy (SNB), define hrUS resolution, and which US criteria should be used. During a 6.5-year period, 131 consecutive patients with 132 >or=1-mm thick or ulcerated cutaneous melanomas, who were followed up at single center, enrolled. All underwent preoperative regional lymph-node SNB. We used recently evaluated ultrasonographic stringent nonstringent SN...
Advanced melanoma patients who failed anti‐PD‐1 therapy have limited options. We analyzed a cohort of 133 advanced receiving monotherapy in referral center between April 2015 and December 2017, included the 26 with confirmed progressive (PD) or stable disease received additional radiotherapy an unmodified mAb regimen. Tumor evaluations were done on radiated nonradiated (RECIST 1.1) lesions, abscopal effect defined as partial (PR) complete response (CR) outside fields. Primary endpoint was CR...
To assess the role of radiotherapy in anti-PD-1-treated melanoma patients, we studied retrospectively a cohort 206 consecutive anti-PD-1 monotherapy-treated advanced patients (59% M1c/d, 50% ≥ 3 metastasis sites, 33% ECOG PS 1, > 1st line, 32% elevated serum LDH) having widely (49%) received concurrent radiotherapy, with RECIST 1.1 evaluation radiated and non-radiated lesions. Overall (OS) progression-free (PFS) survivals were calculated using Kaplan−Meier. Radiotherapy was performed early...
Cell-mediated immunity directed against human papillomavirus 16 (HPV-16) antigens was studied in patients affected with classic vulvar intra-epithelial neoplasia (VIN), also known as bowenoid papulosis (BP). Ten had blood lymphocyte proliferative T cell responses E6/2 (14-34) and/or E6/4 (45-68) peptides, which were identified the present study immunodominant among HPV-16 E6 and E7 large peptides. Ex vivo enzyme-linked immunospot-interferon (IFN)-gamma assay positive three who responses....
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent non-melanoma skin cancer. Treatment options for inoperable advanced cSCC cases are limited. The efficacy of anti-programmed death-1 (PD-1) monoclonal antibodies (mAb) has been reported recently in some patients with cSCC. To evaluate anti-PD-1 mAb a case series and to analyse concurrent radiotherapy. We retrospectively analysed files all treated radiotherapy outside clinical trials our cancer centre before December 31,...
BRAF and MEK are component of the MAPK/ERK pathway inhibitors these proteins have significantly improved outcome metastatic melanoma. We report for first time two sequential episodes pneumonitis presumably induced by trametinib (a inhibitor) vemurafenib in a 50 year-old man. While receiving melanoma, patient developed non-febrile acute respiratory failure context bilateral ground-glass opacities sub pleural reticulations on high resolution computed tomography. An excess lymphocytes was found...
Data regarding elderly melanoma patients treated with anti-PD-1 or anti-CTLA-4 antibodies are in favor of tolerability outcomes that similar to those younger counterparts. However, there very few studies focusing on receiving nivolumab combined ipilimumab (NIVO + IPI). Here, we ask what the current prescribing patterns NIVO IPI population and analyze tolerance profile. This French multicenter retrospective study was conducted 60 aged 80 years older between January 2011 June 2022. The mean...
9537 Background: Radiotherapy (Rx) and anti-PD-1 mAb are potentially synergistic. No study has tested this combination only in pts who failed on mAb, which allows to assess the abscopal effect. We evaluated a cohort of advanced melanoma after failure monotherapy. Methods: Analysis prospective database referral center searching for with confirmed (2 CT-scans) progressive (PD) or stable (SD) disease monotherapy, later received concurrent Rx without modification regimen. Radiologists performed...
One-fifth of cutaneous melanomas have dominant gain-of-function mutations the NRAS oncogene. We report first two cases increasing mutant allele frequency in melanoma metastases and show that chromosomal mechanism this homozygosity is an increased polysomy chromosome 1. observed increase percentage (NRAS-MA%) metastatic progression from 2 patients with harbouring a mutation (p.Q61K case 1 p.Q61R 2). In 1, we NRAS-MA% 18% within node to 81%, 92% 85% respectively three subsequent metastases:...